This week, CV Sciences CVSI released the results of a preclinical study that suggests that CBD can reduce nicotine withdrawal symptoms in smokeless tobacco users.
The study, conducted in collaboration with researchers from the University of California, San Diego and published on Springer Nature, found that CBD prevented nicotine-dependent rats from exhibiting withdrawal symptoms including increased pain sensitivity and weight gain during short-and long-term nicotine restriction.
The company also released its potential plans to develop the world’s first and only FDA-approved treatment for smokeless tobacco addiction.
“We are thrilled with the results of this study done in collaboration with UC San Diego, which marks a significant milestone for our drug development division,” Joseph Dowling, CEO of CV Sciences told Benzinga. “Through continued research and innovation, we are committed to developing a CBD-based therapeutic to address the huge, unmet medical need and global health issue of nicotine addiction.”
Encuentra nuestro contenido en Español en El Planteo:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!